medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2020, Number 4

<< Back Next >>

Rev Mex Urol 2020; 80 (4)

Urinary tract infections after transurethral resection of the bladder: Microbiology, antibiotic resistance, and associated risk factors

Martínez-Delgado GH, Garza-Gangemi AM, Castillejos-Molina RA

Language: English
References: 30
Page: 1-12
PDF size: 163.90 Kb.


ABSTRACT

Objective: To analyze the microbiology and incidence of antibiotic resistance in patients that underwent transurethral resection of bladder tumor (TURBT) and identify risk factors for urinary tract infection (UTI) after the procedure.
Methodological design: A retrospective, analytic, descriptive study on data from 199 patients that underwent TURBT at a tertiary care hospital in Mexico City between 2017-2019. The microbiologic characteristics of isolation frequency and drug-resistance pattern were analyzed before and after the procedure. Binary logistic regression was carried out to identify independent risk factors for UTI.
Results: Of the 199 patients evaluated, 28 (14%) had a positive urine culture (PUC) before the procedure and the most frequently isolated uropathogens were Escherichia coli (48%), Enterococcus faecalis (24%), and Proteus mirabilis (7%). UTI after TURBT was reported in the 20 patients (10%) that made up group 1. The most frequent pathogen was E. coli (45%), which was resistant to trimethoprim/sulfamethoxazole (60%) and ciprofloxacin (40%). Other isolated pathogens were E. faecalis (27%) and P. mirabilis (9%). The control group included the 179 (90%) patients that did not have a UTI. PUC was statistically significant in relation to necrosis (p=0.001) and muscle-invasive bladder cancer (p=0.03). In the multivariate analysis, PUC was associated with UTI after TURBT (OR 7.04 [95% CI 2.11-23.29]).
Limitations: A retrospective study with information limited to that in the case records.
Originality and value: There are few articles on TURBT-associated UTI in the international literature and none in Mexico, the present study being the first.
Conclusions: The prevalence of UTI after TURBT was 10%. Pre-procedure PUC was the most highly associated risk factor for UTI after TURBT. The most frequently isolated uropathogens were E. coli, E. faecalis, and P. mirabilis. E. coli was most resistant to trimethoprim/sulfamethoxazole (60%) and ciprofloxacin (40%).


REFERENCES

  1. GLOBOCAN. Incident cancer cases and deaths worldwide in both sexes and all ages and prevalent cancer cases (5-year) worldwide in both sexes and all ages. 2018. Available from: https://gco.iarc.fr/today/data/factsheets/ populations/900-world-fact-sheets.pdf

  2. Jiménez Ríos MÁ, Solares Sánchez ME, Martínez Cervera PF, Espinosa Ostos D, Feria Bernal G, Salvador A-M, et al. Panorama epidemiológico del cáncer genitourinario en la Zona Centro de México. Revista mexicana de urología. 2011;71:3–6.

  3. Snyder C, Harlan L, Knopf K, Potosky A, Kaplan R. Patterns of Care for the Treatment of Bladder Cancer. Journal of Urology. 2003 May;169(5):1697–701. doi: https://doi. org/10.1097/01.ju.0000056727.30546.b7

  4. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology. 2005 Dec;66(6):4–34. doi: https://doi.org/10.1016/j.urology.2005.07.062

  5. Goldwasser B, Bogokowsky B, Nativ O, Sidi AA, Jonas P, Many M. Urinary Infections Following Transurethral Resection of Bladder Tumors—Rate and Source. Journal of Urology. 1983 Jun;129(6):1123–4. doi: https://doi. org/10.1016/s0022-5347(17)52602-6

  6. Appell RA, Flynn JT, Paris AMI, Blandy JP. Occult Bacterial Colonization of Bladder Tumors. Journal of Urology. 1980 Sep;124(3):345– 6. doi: https://doi.org/10.1016/s0022- 5347(17)55440-3

  7. Alsaywid B, Smith GrahameHH. Antibiotic prophylaxis for transurethral urological surgeries: Systematic review. Urol Ann. 2013;5(2):61. doi: https://doi.org/10.4103/0974-7796.109993

  8. Junuzovic D, Hasanbegovic M, Zvizdic S, Hamzic S, Zunic L. The Connection Between Endourological Procedures and Occurrence of Urinary Infections. Mater Sociomed. 2014;26(4):237. doi: https://doi.org/10.5455/ msm.2014.237-241

  9. Kohada Y, Goriki A, Yukihiro K, Ohara S, Kajiwara M. The risk factors of urinary tract infection after transurethral resection of bladder tumors. World J Urol. 2019 Dec;37(12):2715–9. doi: https://doi.org/10.1007/s00345-019- 02737-3

  10. Junuzovic D, Hasanbegovic M, Kovacevic J, Prstojevic P. The Incidence of Acquired Urinary Tract Infections in Patients After Transurethral Resection of Bladder Tumors. Mater Sociomed. 2011;23(2):91. doi: https://doi.org/10.5455/ msm.2011.23.91-92

  11. Kim BS, Tae BS, Ku JH, Kwak C, Kim HH, Jeong CW. Rate and association of lower urinary tract infection with recurrence after transurethral resection of bladder tumor. Investig Clin Urol. 2018;59(1):10. doi: https://doi.org/10.4111/ icu.2018.59.1.10

  12. Panach-Navarrete J, Valls-González L, Sánchez- Cano E, Medina-González M, Castelló-Porcar A, Martínez-Jabaloyas JM. Comparison of three different antibiotic protocols in transurethral resection of bladder tumour and the possible infectious risk factors: A non-randomized, prospective study. CUAJ. 2018 Jun 7;12(11). [accessed 1 Jul 2020] Available from: https:// cuaj.ca/index.php/journal/article/view/5207

  13. Dick A, Barnes R, Hadley H, Bergman RT, Ninan CA. Complications of Transurethral Resection of Bladder Tumors: Prevention, Recognition and Treatment. Journal of Urology. 1980 Dec;124(6):810–1. doi: https://doi. org/10.1016/s0022-5347(17)55677-3

  14. Sopeña-Sutil R, Medina-Polo J, Justo-Quintas J, Gil-Moradillo J, Garcia-Gonzalez L, Benítez- Sala R, et al. Healthcare-Associated Infections after Lower Urinary Tract Endoscopic Surgery: Analysis of Risk Factors, Associated Microorganisms and Patterns of Antibiotic Resistance. Urol Int. 2018;100(4):440–4. doi: https://doi.org/10.1159/000488251

  15. MacDERMOTT JP, Ewing RE, Somerville JFS, Gray BK. Cephradine Prophylaxis in Transurethral Procedures for Carcinoma of the Bladder. British Journal of Urology. 1988 Aug;62(2):136–9. doi: https://doi.org/10.1111/ j.1464-410x.1988.tb04292.x

  16. Delavierre D, Huiban B, Fournier G, Le Gall G, Tande D, Mangin P. [The value of antibiotic prophylaxis in transurethral resection of bladder tumors. Apropos of 61 cases]. Prog Urol. 1993 Sep;3(4):577–82.

  17. Upton JD, Das S. Prophylactic antibiotics in transurethral resection of bladder tumors: Are they necessary? Urology. 1986 May;27(5):421– 3. doi: https://doi.org/10.1016/0090- 4295(86)90406-1

  18. Castillejos-Molina R. Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURBT) - Full Text View - ClinicalTrials.gov. 2019. [accessed 1 Jul 2020] Available from: https://clinicaltrials.gov/ct2/ show/NCT04209192

  19. Yamamoto S, Shigemura K, Kiyota H, Wada K, Hayami H, Yasuda M, et al. Essential Japanese guidelines for the prevention of perioperative infections in the urological field: 2015 edition. Int J Urol. 2016 Oct;23(10):814–24. doi: https:// doi.org/10.1111/iju.13161

  20. Wada K, Uehara S, Kira S, Matsumoto M, Sho T, Kurimura Y, et al. Prospective multi-institutional analysis according to the ‘Japanese guidelines for prevention of perioperative infections in urological field’. Jpn j urol. 2013;104(3):505–12. doi: https://doi. org/10.5980/jpnjurol.104.505

  21. El Basri A, Petrolekas A, Cariou G, Doublet JD, Hoznek A, Bruyere F. Clinical Significance of Routine Urinary Bacterial Culture After Transurethral Surgery: Results of a Prospective Multicenter Study. Urology. 2012 Mar;79(3):564–9. doi: https://doi. org/10.1016/j.urology.2011.11.018

  22. Schilling JD, Hultgren SJ. Recent advances into the pathogenesis of recurrent urinary tract infections: the bladder as a reservoir for uropathogenic Escherichia coli. International Journal of Antimicrobial Agents. 2002 Jun;19(6):457–60. doi: https://doi. org/10.1016/s0924-8579(02)00098-5

  23. Mulvey MA, Schilling JD, Martinez JJ, Hultgren SJ. Bad bugs and beleaguered bladders: Interplay between uropathogenic Escherichia coli and innate host defenses. Proceedings of the National Academy of Sciences. 2000 Aug 1;97(16):8829–35. doi: https://doi. org/10.1073/pnas.97.16.8829

  24. Concia E, Azzini AM. Aetiology and antibiotic resistance issues regarding urological procedures. Journal of Chemotherapy. 2014 Oct;26(sup1):S14–23. doi: https://doi.org/10.1 179/1120009x14z.000000000233

  25. ECDC. Surveillance of antimicrobial resistance in Europe 2018. European Centre for Disease Prevention and Control. 2019. [accessed 1 Jul 2020] Available from: https://www.ecdc. europa.eu/en/publications-data/surveillanceantimicrobial- resistance-europe-2018

  26. Garza-Montúfar ME, Treviño-Valdez PD, Garza-Salinas LHD la. Comorbidities and antimicrobial resistance in urological outpatients with positive urine culture. Rev Med Inst Mex Seguro Soc. 2018 Dec 26;56(4):347–53.

  27. Cornejo-Dávila V, Palmeros-Rodríguez MA, Uberetagoyena-Tello de Meneses I, Mayorga- Gómez E, Garza-Sáinz G, Osornio-Sánchez V, et al. Management of complicated urinary tract infections in a referral center in Mexico. Int Urol Nephrol. 2015 Feb;47(2):229–33. doi: https:// doi.org/10.1007/s11255-014-0883-y

  28. Páramo Rivas F, Tovar Serrano A, Rendón Macías ME. Resistencia antimicrobiana en pacientes con infección de vías urinarias hospitalizados en el servicio de Medicina Interna del Nuevo Sanatorio Durango, de enero a diciembre de 2013. Medicina interna de México. 2015;31(1):34–40.

  29. Soave A, John L-M, Dahlem R, Minner S, Engel O, Schmidt S, et al. The Impact of Tumor Diameter and Tumor Necrosis on Oncologic Outcomes in Patients With Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. Urology. 2015 Jul;86(1):92–8. doi: https://doi.org/10.1016/j.urology.2015.03.036

  30. Eustace A, Irlam JJ, Taylor J, Denley H, Agrawal S, Choudhury A, et al. Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. Radiotherapy and Oncology. 2013 Jul;108(1):40–7. doi: https:// doi.org/10.1016/j.radonc.2013.05.017




2020     |     www.medigraphic.com